CME / ABIM MOC / CE

Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms

Authors: Hagop M. Kantarjian, MD; Courtney D. DiNardo, MD, MSCE; Guillermo Garcia-Manero, MD; Elias J. Jabbour, MD; Susan O'Brien, MD; Srdan Verstovsek, MD, PhD
CME / ABIM MOC / CE Released: 2/24/2023
Valid for credit through: 2/24/2024

Credits Available

Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 2.50 ABIM MOC points

Nurses - 2.50 ANCC Contact Hour(s) (2.5 contact hours are in the area of pharmacology)

Pharmacists - 2.50 ACPE Contact Hour(s) (0.250 CEUs)

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners (NPs), pharmacists, and other healthcare practitioners (HCPs) involved in the care of patients with hematological malignancies and disorders.

The goal of this activity is for learners to be better able to manage care for patients with hematologic malignancies by incorporating updates on the most meaningful and practice-changing data in hematology from 2022.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Emerging clinical trial data for hematologic malignancies
- Methods to assess treatment response in patients with hematologic malignancies and disorders
- Treatment-related adverse events of agents used in hematologic malignancies and disorders
Demonstrate greater confidence in their ability to
- Individualize treatment for patients with hematologic malignancies and disorders

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Hagop M. Kantarjian, MD

Professor and Chair
Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Hagop M. Kantarjian, MD, has no relevant financial relationships.

Courtney D. DiNardo, MD, MSCE

Associate Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Courtney D. DiNardo, MD, MSCE, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Agios Pharmaceuticals/Servier; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Genentech; Genmab; Novartis; Notable Labs; Takeda
Research funding from: AbbVie, Inc.; Agios Pharmaceuticals/Servier; Astex Pharmaceuticals; Bristol Myers Squibb Company; Calithera Biosciences; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Loxo Oncology
Stock options from: Notable Labs

Guillermo Garcia-Manero, MD

Professor of Medicine
Chief, Section of Myelodysplastic Syndromes
Department of Leukemia
Division of Cancer Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Guillermo Garcia-Manero, MD, has the following relevant financial relationships:
Research funding from: AbbVie, Inc.; APR Applied Pharma Research s.a.; Astex Pharmaceuticals; Bristol Myers Squibb Company; Curis, Inc.; Genentech; Gilead Sciences, Inc.; Novartis

Elias J. Jabbour, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Elias Jabbour, MD, has no relevant financial relationships.

Susan O’Brien, MD

Professor of Medicine
University of California Irvine School of Medicine
Associate Director, Clinical Science
Chao Family Comprehensive Cancer Center
Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research
Chao Family Endowed Chair for Cancer Clinical Science
Orange, California

Disclosures

Susan O’Brien, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Alexion Pharmaceuticals, Inc.; Amgen, Inc.; Aptose Biosciences Inc.; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Autolus Therapeutics; Bristol Myers Squibb Company; Celgene Corporation; DynaMed; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Johnson & Johnson; Juno Therapeutics, Inc.; Lilly; MEI Pharma; Merck; NOVA; Pfizer, Inc.; Pharmacyclics, Inc.; TG Therapeutics, Inc.; Vaniam Group; Verastem, Inc.; Vida Ventures
Research funding from: Acerta; Alliance; BeiGene (Beijing) Co., Ltd.; Caribou Biosciences; Gilead Sciences, Inc.; Kite Pharma, Inc.; Loxo Oncology; Mustang Bio, Inc.; Nurix; Pfizer, Inc.; Pharmacyclics, Inc.; Regeneron Pharmaceuticals, Inc.; TG Therapeutics, Inc.

Srdan Verstovsek, MD, PhD

Professor of Medicine
Director, Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Srdan Verstovsek, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: CTI Biopharma Corp.; Incyte Corporation; PharmaEssentia; Novartis; Sierra Oncology, Inc.
Research funding from: AstraZeneca Pharmaceutials LP; Blueprint Medicines; Celgene Corporation; CTI BioPharma Corp.; Genentech; Gilead Sciences, Inc.; Incyte Corporation; Italfarmaco S.p.A.; Novartis; NS Pharma, Inc.; PharmaEssentia; Protagonist Therapeutics; Roche; Sierra Oncology, Inc.

Editor

John Churchwell, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, PhD, has the following relevant financial relationships:
Employed by an ineligible company: Medtronic (former)

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 2.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.50 contact hours are in the area of pharmacology. 

Contact This Provider

For Pharmacists

Medscape, LLC designates this continuing education activity for 2.50 contact hour(s) (0.250 CEUs) (Universal Activity Number JA0007105-0000-23-087-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms

Authors: Hagop M. Kantarjian, MD; Courtney D. DiNardo, MD, MSCE; Guillermo Garcia-Manero, MD; Elias J. Jabbour, MD; Susan O'Brien, MD; Srdan Verstovsek, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 2/24/2023

Valid for credit through: 2/24/2024

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Acute Myeloid Leukemia

How will we treat AML in 2023?
Courtney D. DiNardo, MD, MSCE

Myelodysplastic Syndrome

What are the latest advances in low-risk and high-risk MDS?
Guillermo Garcia-Manero, MD

Chronic Myeloid Leukemia

How might CML treatment evolve in 2023?
Hagop M. Kantarjian, MD

Acute Lymphoblastic Leukemia

Dr Jabbour explores the newest data in ALL.
Elias Jabbour, MD

Chronic Lymphocytic Leukemia

Dr O’Brien looks at the latest advances in CLL.
Susan O’Brien, MD

Myeloproliferative Neoplasms

What is the latest management of PV, ET, and low-risk MF?
Srdan Verstovsek, MD, PhD

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 9

CME / ABIM MOC / CE Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

​​​​​​​​Hagop M. Kantarjian, MD

Courtney D. DiNardo, MD, MSCE

Guillermo Garcia-Manero, MD

Elias J. Jabbour, MD

Susan O’Brien, MD

Srdan Verstovsek, MD, PhD

Editor

John Churchwell, PhD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

​​​​​​​​Hagop M. Kantarjian, MD

Courtney D. DiNardo, MD, MSCE

Guillermo Garcia-Manero, MD

Elias J. Jabbour, MD

Susan O’Brien, MD

Srdan Verstovsek, MD, PhD

Editor

John Churchwell, PhD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms

Contents of This CME Activity

Acute Myeloid Leukemia

Myelodysplastic Syndrome

Chronic Myeloid Leukemia

Acute Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Myeloproliferative Neoplasms

Educational Impact Challenge

Hagop M. Kantarjian, MD

Hagop M. Kantarjian, MD